Dr. Infante from Sarah Cannon Research Institute Talks About BRAF Mutation Testing
Jeffrey Infante, MD, director of drug development at the Sarah Cannon Research Institute talks about BRAF mutation testing.
Dr. Infante says that there is a subset of melanoma patients (about half) that have the BRAF mutation. He adds it can be tested easily around the country by multiple labs. If it turns out that a patient has a genetic change that is a BRAF mutation, there are drugs that can help the patient. While the drugs aren't FDA approved yet, there are many trials ongoing where patients can get access to those drugs.